Clinical Trial Update: Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AK105 in combination with Anlotinib and radiotherapy as adjuvant therapy for MGMT unmethylated newly diagnosed glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anlotinib (anlotinib)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: MGMT-Unmethylated Glioblastoma | Phase 2 | Status: UNKNOWN